203 related articles for article (PubMed ID: 26968792)
1. Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Trial.
Morris J; Rudebeck M; Neudorf S; Moore T; Duerst R; Shah AJ; Graham M; Aquino V; Morris C; Olsson B
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1247-1256. PubMed ID: 26968792
[TBL] [Abstract][Full Text] [Related]
2. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
Lucchese A; Matarese G; Manuelli M; Ciuffreda C; Bassani L; Isola G; Cordasco G; Gherlone E
Minerva Stomatol; 2016 Feb; 65(1):43-50. PubMed ID: 26862696
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation.
Srinivasan A; Kasow KA; Cross S; Parrish M; Wang C; Srivastava DK; Cai X; Panetta JC; Leung W
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1309-14. PubMed ID: 22542710
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.
Lucchese A; Matarese G; Ghislanzoni LH; Gastaldi G; Manuelli M; Gherlone E
Leuk Lymphoma; 2016; 57(4):820-7. PubMed ID: 26428409
[TBL] [Abstract][Full Text] [Related]
5. Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.
Nguyen DT; Shayani S; Palmer J; Dagis A; Forman SJ; Epstein J; Spielberger R
Support Care Cancer; 2015 Nov; 23(11):3141-7. PubMed ID: 25791390
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
[TBL] [Abstract][Full Text] [Related]
7. Palifermin in children undergoing autologous stem cell transplantation: a matched-pair analysis.
Czyzewski K; Debski R; Krenska A; Wysocki M; Styczynski J
Anticancer Res; 2014 Dec; 34(12):7379-82. PubMed ID: 25503176
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
Abidi MH; Agarwal R; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Ratanatharathorn V; Zonder J; Uberti J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):56-61. PubMed ID: 22892551
[TBL] [Abstract][Full Text] [Related]
9. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in Children.
Saber W; Zhang MJ; Steinert P; Chen M; Horowitz MM
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1460-1466. PubMed ID: 27090960
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Safety Outcomes in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation Treated with Palifermin to Prevent Oral Mucositis.
Stiff PJ; Leinonen M; Kullenberg T; Rudebeck M; de Chateau M; Spielberger R
Biol Blood Marrow Transplant; 2016 Jan; 22(1):164-9. PubMed ID: 26303102
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.
Hochberg J; Zahler S; Geyer MB; Chen N; Krajewski J; Harrison L; Militano O; Ozkaynak MF; Cheerva AC; Talano J; Moore TB; Gillio AP; Walters MC; Baxter-Lowe LA; Hamby C; Cairo MS
Bone Marrow Transplant; 2019 Feb; 54(2):226-235. PubMed ID: 29899571
[TBL] [Abstract][Full Text] [Related]
13. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
Blazar BR; Weisdorf DJ; Defor T; Goldman A; Braun T; Silver S; Ferrara JL
Blood; 2006 Nov; 108(9):3216-22. PubMed ID: 16835378
[TBL] [Abstract][Full Text] [Related]
14. Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.
Nasilowska-Adamska B; Szydlo R; Rzepecki P; Czyz A; Tomaszewska A; Markiewicz M; Torosian T; Bieniaszewska M; Hellman A; Jedrzejczak WW; Holowiecki J; Komarnicki M; Warzocha K; Marianska B
Ann Transplant; 2011; 16(4):47-54. PubMed ID: 22210421
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
Beaven AW; Shea TC
Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
[TBL] [Abstract][Full Text] [Related]
16. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation.
Schmidt V; Niederwieser D; Schenk T; Behre G; Klink A; Pfrepper C; Hinke A; Beelen DW; Junghanss C; Uharek L; Krüger WH; Hochhaus A; Sayer HG;
Bone Marrow Transplant; 2018 Sep; 53(9):1188-1192. PubMed ID: 29545592
[No Abstract] [Full Text] [Related]
19. Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study.
Lauritano D; Petruzzi M; Di Stasio D; Lucchese A
Int J Oral Sci; 2014 Mar; 6(1):27-30. PubMed ID: 24357856
[TBL] [Abstract][Full Text] [Related]
20. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
